首页|靶向共有新抗原的肿瘤疫苗和细胞治疗新进展

靶向共有新抗原的肿瘤疫苗和细胞治疗新进展

扫码查看
共有新抗原是肿瘤患者中共同呈现的免疫原性表位,通常由肿瘤驱动基因的热点突变产生,仅在肿瘤组织中表达,作为肿瘤特异性抗原刺激机体产生免疫反应.共有新抗原因其"现货型"、通用性、高特异性、强免疫原性等优势受到研究人员的青睐.本文阐述了共有新抗原的来源、特点及常见的共有新抗原,着重阐述了靶向共有新抗原疫苗治疗和细胞治疗的研究进展,列举相关的临床试验,并简述了提高共有新抗原疫苗与细胞治疗的策略.
Progress in tumor vaccines and cell therapies targeting shared neoantigens
Shared neoantigens are immunogenic epitopes that are commonly found in tumor patients and are usually genera-ted by hotspot mutations in tumor driver genes.They are expressed only in tumor tissues and act as tumor-specific anti-gens to stimulate an immune response.Shared neoantigens are favored by researchers because of their"off-the-shelf"avail-ability,universality,highly specificity,and strong immunogenicity.This review describes in detail the sources,characteris-tics and common shared neoantigens,focusing on the research progress of novel therapeutic methods such as vaccine thera-py and cell therapy targeting shared neoantigens.Also,this article lists the relevant clinical trials,and briefly describes the strategies to improve the vaccine and cell therapy against shared neoantigens.

shared neoantigenstherapeutic tumor vaccineshotspot mutationsadoptive cell therapy

曹鑫、刘芹、刘宝瑞

展开 >

南京大学医学院附属鼓楼医院肿瘤中心,江苏南京 210008

共有新抗原 肿瘤治疗性疫苗 热点突变 过继细胞治疗

2024

中华肿瘤防治杂志
中华预防医学会 山东省肿瘤防治研究院

中华肿瘤防治杂志

CSTPCD北大核心
影响因子:1.292
ISSN:1673-5269
年,卷(期):2024.31(17)